

## ISSUE AND REPURCHASE OF CLASS C SHARES

**Cinclus Pharma Holding AB (publ) announces that the company has resolved to issue and immediately thereafter repurchase 854,430 class C shares. The shares are issued and repurchased in accordance with the long-term incentive programmes, PSP 2024/2027 and ESOP 2024/2027, which were adopted by the extraordinary general meeting on 3 June 2024. The size of the share issue has been determined with account taken to Cinclus Pharma's total need for share delivery under the company's long-term incentive programmes hedged with class C shares.**

Handelsbanken subscribes for the entire issue of new class C shares at a subscription price of approximately SEK 0.019414 per share, equal to the quota value of the shares. The entire issue of class C shares will thereafter be repurchased by Cinclus Pharma for the same price per share.

The purpose of the share issue is to enable the future delivery of ordinary shares to participants in PSP 2024/2027 and ESOP 2024/2027. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants in PSP 2024/2027 and ESOP 2024/2027. The class C shares do not entitle to dividends.

**For additional information, please contact:**

---

Christer Ahlberg, CEO  
Phone: +46 70 675 33 30  
e-mail: [christer.ahlberg@cincluspharma.com](mailto:christer.ahlberg@cincluspharma.com)

Charlotte Stjerngren, IR  
Phone: +46 70 876 87 87  
e-mail: [charlotte.stjerngren@cincluspharma.com](mailto:charlotte.stjerngren@cincluspharma.com)

## About Cinclus Pharma

---

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit [www.cincluspharma.com](http://www.cincluspharma.com).

## Attachments

---

**Issue and repurchase of class C shares**